

## ASX Release

### Anatara receives APVMA approval for Detach®

BRISBANE & MELBOURNE, 29<sup>th</sup> October 2018: Anatara Lifesciences (ASX:ANR) is pleased to announce that the Australian Pesticides and Veterinary Medicines Authority (APVMA) has registered Detach® with the approved label, *“To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”*.

“APVMA approval of Detach® was one of the major corporate milestones that we had promised to deliver as part of Anatara’s ASX listing process in 2014. Today’s announcement is the culmination of many years of hard work from our team, both past and present, and is a very significant achievement for the company,” said Sue MacLeman, Anatara’s Chair.

On 15 May 2018, Anatara announced that it had signed an exclusive licensing agreement with leading global animal health company, Zoetis Inc., for the worldwide development, manufacture, distribution, and marketing of Detach® for livestock and horses. Under the terms of this agreement, Zoetis has exclusive global rights which includes the Australian market and Anatara is not able to disclose any information relating to product development or product release.

“We are delighted to have secured APVMA approval for Detach® and would especially like to thank the CRC for High Integrity Australian Pork (Pork CRC) for their assistance in its development”, said Tracie Ramsdale, Interim CEO. The Pork CRC ([www.porkcrc.com.au](http://www.porkcrc.com.au)) is made up of Australia’s largest pork producers, feed manufacturers, key government, research and farming industry bodies. Anatara entered into a Commercial Collaboration Agreement with the Pork CRC in 2015. This relationship enabled Anatara to work closely with key players in the Australian pork industry to locate suitable clinical trial sites and conduct clinical trials, leading to APVMA approval.

Under the terms of the Commercial Collaboration Agreement, the Pork CRC was issued with 500,000 options at an exercise price of \$0.50. 125,000 of these options were exercised within the first year. Exercise of the remaining 375,000 options was conditional upon APVMA approval which had not been received prior to their expiry on the 18<sup>th</sup> September 2018. Anatara will now issue 375,000 options to the Pork CRC, with an exercise price of \$0.50 and an expiry date of 6 months from the date of issue.

**For more information please contact:**

<b>Investor inquiries</b>	<b>Media inquiries</b>
Sue MacLeman Chair Anatara Lifesciences +61 (0) 437 211 200 info@anatara.com	Jane Lowe Managing Director IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

### **About Anatara Lifesciences**

Anatara Lifesciences (ASX:ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications.

For more information, please visit [www.anataralifesciences.com](http://www.anataralifesciences.com),